Latham & Watkins represented the underwriters in the offering. Eliem Therapeutics, Inc., a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Absci, while Latham & Watkins represented the underwriters in the offering. Absci Corporation (Absci), the synthetic biology company unlocking the potential of proteins...
You must be a Standard 1 Year member to access this content.
Latham & Watkins LLP represented Imago BioSciences, Inc. in the offering. Imago BioSciences, Inc. (Imago) (NASDAQ: IMGO), a clinical stage biopharmaceutical company discovering new medicines for the...
You must be a Standard 1 Year member to access this content.
Latham & Watkins LLP represented GSK in the transaction. Alector, Inc. and GlaxoSmithKline plc, announced a strategic global collaboration for the development and commercialization of two...
You must be a Standard 1 Year member to access this content.
Latham & Watkins LLP represented GSK in the transaction. Alector, Inc. and GlaxoSmithKline plc, announced a strategic global collaboration for the development and commercialization of two...
You must be a Standard 1 Year member to access this content.
